Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
P/B ratio for Trevi Therapeutics, Inc. (TRVI)
P/B ratio as of 2023: 1.61
According to Trevi Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.61. At the end of 2022 the company had a P/B ratio of 1.16.
P/B ratio history for Trevi Therapeutics, Inc. from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.61 |
| 2022 | 1.16 |
| 2021 | 1.05 |
| 2020 | 1.60 |
| 2019 | 0.81 |
| 2018 | 4.09 |
| 2017 | 4.79 |
| 2016 | -7.31 |